More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$332759865
EPS
-1.01
P/E ratio
--
Price to sales
5.81
Dividend yield
--
Beta
0.655073
Previous close
$8.88
Today's open
$8.80
Day's range
$8.64 - $9.08
52 week range
$5.03 - $9.34
show more
CEO
Kevin J. Knopp
Employees
246
Headquarters
Burlington, MA
Exchange
NASDAQ Global Market
Shares outstanding
37813621
Issue type
Common Stock
Healthcare
Medical Equipment & Supplies
908 Devices Q2 Earnings Call Highlights
908 Devices NASDAQ: MASS reported second-quarter revenue growth of 23% as demand from U.S. state and local government customers, FTIR product shipments and its recently acquired NIRLab platform supported results. The company also raised the low end of its full-year revenue outlook while continuing to exclude potential revenue from the U.S. military's AVCAD program from its core guidance.
MarketBeat • 14 hours ago

908 Devices Inc. (MASS) Q2 2026 Earnings Call Transcript
908 Devices Inc. (MASS) Q2 2026 Earnings Call Transcript
Seeking Alpha • 11 hours ago

908 Devices Reports Second Quarter 2026 Financial Results and Raises Low End of 2026 Revenue Outlook
BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety, and defense tech applications, today reported financial results for the quarter ended June 30, 2026. “We delivered another strong quarter, growing revenue 23% year-over-year, while narrowing our Adjusted EBITDA loss by more than half compared to a year ago,” said Kevin J. Knopp, CEO and Co-founder. “Our momentum.
Business Wire • 18 hours ago

908 Devices Inc. (MASS) Reports Q2 Loss, Tops Revenue Estimates
908 Devices Inc. (MASS) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to a loss of $0.18 per share a year ago.
Zacks Investment Research • 16 hours ago

908 Devices Inc. (MASS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
908 Devices (MASS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Investment Research • Aug 4, 2026

908 Devices to Participate in the Canaccord Genuity 46th Annual Growth Conference
BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, announced it will participate in the upcoming Canaccord Genuity 46th Annual Growth Conference. 908 Devices' management is scheduled to present on Wednesday, August 12 at 12:30 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Inv.
Business Wire • Jul 29, 2026

908 Devices to Report Second Quarter 2026 Financial Results on August 11, 2026
BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, announced it will report financial results for the second quarter 2026 before market open on Tuesday, August 11, 2026. Company management will webcast a corresponding conference call beginning at 8:30 a.m. Eastern Time. Live audio of the webcast will be available on the “Investors” s.
Business Wire • Jul 28, 2026

908 Devices (MASS) Upgraded to Buy: Here's Why
908 Devices (MASS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks Investment Research • Jun 4, 2026

908 Devices Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, announced that on June 1, 2026, the Compensation Committee of its Board of Directors granted options to four new non-executive employees to purchase an aggregate of 179,912 shares of 908 Devices' common stock. The options were granted as a material inducement to employment with 908 D.
Business Wire • Jun 2, 2026

908 Devices to Present at the 16th Annual East Coast IDEAS Investor Conference
BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, announced that CEO and Co-founder Kevin J. Knopp and CFO Joe Griffith will present and host investor meetings at the 16th Annual East Coast IDEAS Conference on Wednesday, June 10, 2026. The Company presentation is scheduled to begin at 8:35 a.m. Eastern Time. The presentation is webc.
Business Wire • May 28, 2026

¹ Disclosures

Open an M1 investment account to buy and sell 908 Devices Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.